Drug Profile
BIII 277CL
Alternative Names: BIII 277; BIII 281CLLatest Information Update: 10 Mar 1999
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim
- Class Anti-ischaemics; Neuroprotectants; Small molecules
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Stroke